Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

doi:10.7326/0003-4819-156-10-201205150-00013

. 2012 May 15;156(10):743-5.

doi: 10.7326/0003-4819-156-10-201205150-00013.

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

Anna S F Lok¹, John W Ward, Robert P Perrillo, Brian J McMahon, T Jake Liang

Affiliations

Affiliation

¹ Division of Gastroenterology and Hepatology, University of Michigan Health System, 3110G Taubman Center, SPC 5368, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. aslok@umich.edu

PMID: 22586011
PMCID: PMC3469313
DOI: 10.7326/0003-4819-156-10-201205150-00013

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

Anna S F Lok et al. Ann Intern Med. 2012.

. 2012 May 15;156(10):743-5.

doi: 10.7326/0003-4819-156-10-201205150-00013.

Authors

Anna S F Lok¹, John W Ward, Robert P Perrillo, Brian J McMahon, T Jake Liang

Affiliation

¹ Division of Gastroenterology and Hepatology, University of Michigan Health System, 3110G Taubman Center, SPC 5368, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. aslok@umich.edu

PMID: 22586011
PMCID: PMC3469313
DOI: 10.7326/0003-4819-156-10-201205150-00013

No abstract available

PubMed Disclaimer

Cited by

Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.
Vassilopoulos D, Calabrese LH. Vassilopoulos D, et al. Curr Rheumatol Rep. 2013 Apr;15(4):319. doi: 10.1007/s11926-013-0319-1. Curr Rheumatol Rep. 2013. PMID: 23436024 Review.
RISE registry reveals potential gaps in medication safety for new users of biologics and _targeted synthetic DMARDs.
Schmajuk G, Li J, Evans M, Anastasiou C, Izadi Z, Kay JL, Hammam N, Yazdany J. Schmajuk G, et al. Semin Arthritis Rheum. 2020 Dec;50(6):1542-1548. doi: 10.1016/j.semarthrit.2020.03.003. Epub 2020 Mar 19. Semin Arthritis Rheum. 2020. PMID: 32234243 Free PMC article.
Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.
Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children; National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics. Siberry GK, et al. Pediatr Infect Dis J. 2013 Nov;32 Suppl 2(0 2):i-KK4. doi: 10.1097/01.inf.0000437856.09540.11. Pediatr Infect Dis J. 2013. PMID: 24569199 Free PMC article. No abstract available.
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?
Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Di Bisceglie AM, et al. Hepatology. 2015 Feb;61(2):703-11. doi: 10.1002/hep.27609. Hepatology. 2015. PMID: 25412906 Free PMC article. Review.
Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.
Sanagawa A, Hotta Y, Kataoka T, Maeda Y, Kondo M, Kawade Y, Ogawa Y, Nishikawa R, Tohkin M, Kimura K. Sanagawa A, et al. Cancer Med. 2018 Jun;7(6):2269-2279. doi: 10.1002/cam4.1429. Epub 2018 Apr 16. Cancer Med. 2018. PMID: 29663729 Free PMC article.

See all "Cited by" articles

References

1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65. [PMID: 19399803] - PubMed
1. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo-therapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307. [PMID: 11055239] - PubMed
1. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–9. [PMID: 20556450] - PubMed
1. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246–52. [PMID: 12395336] - PubMed
1. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphopro-liferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170–80. [PMID: 21115603] - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

ZIA DK054500-16/ImNIH/Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65. [PMID: 19399803] - PubMed

[2] Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65. [PMID: 19399803] - PubMed

[3] Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo-therapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307. [PMID: 11055239] - PubMed

[4] Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo-therapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307. [PMID: 11055239] - PubMed

[5] Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–9. [PMID: 20556450] - PubMed

[6] Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–9. [PMID: 20556450] - PubMed

[7] Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246–52. [PMID: 12395336] - PubMed

[8] Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002;36:1246–52. [PMID: 12395336] - PubMed

[9] Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphopro-liferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170–80. [PMID: 21115603] - PMC - PubMed

[10] Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphopro-liferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170–80. [PMID: 21115603] - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

Affiliation

Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable

Authors

Affiliation

Similar articles

Cited by

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

References

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical